INTRODUCTION
The first artificial RBCs prepared by microencapsulation of hemolysate have oxygen dissociation curve similar to RBCs [1] . However, these artificial RBCs, even with diameters of down to one micron, survived for a short time in the circulation after intravenous injection [2] . Our study shows that the long circulation time of RBCs is due to the presence of neuraminic acid on the membrane [3] . This led us to study the effects of changing surface properties of the artificial RBCs [2, 3] . This has resulted in significant increases in circulation time, but still not sufficient for clinical uses [3] . Djordjevich and Miller [4] increased the circulation time further by preparing smaller lipid membrane Hb artificial cells with diameter of about 0.2 micron. One of the next important developments is the incorporation of PEG onto the lipid membrane artificial cells, resulting in useful increases in the circulation time [5] . Ongoing efforts are being carried out in preclinical studies towards clinical trial [6, 7] . We have used a biodegradable polymer, polylactic acid (PLA), for the microencapsulation of Hb, enzymes and other biologically active material since 1976 [8] . More recently, we started to prepare nanodimension artificial RBCs of less than 200 nanometer mean diameter using PLA membrane and other biodegradable polymers [9Á11]. We have replaced most of the 6g/dl of lipid membrane in Hb lipid vesicles with 1.6g/dl of biodegradable polymeric membrane material. This marked decrease in the lipid component would lessen effects on the RES and lessen lipid peroxidation in ischemiareperfusion. Unlike lipid membrane, biodegradable polymeric membrane is permeable to glucose. Thus, the inclusion of RBC enzymes prevents MetHb formation even at 37 o C, and we can also convert MetHb to Hb at 37 o C [12Á 14]. In addition, unlike lipid membrane, the nanocapsule membrane allows plasma factors like ascorbic acid to enter the nanocapsules to prevent MetHb formation. In order to increase the circulation time, we synthesized a new PEG-PLA copolymer to prepare NanoHb [12] . After extensive research, we now have a circulation time in rats that is double that of glutaraldehye crosslinked PolyHb [12Á14] .
In this report, we carried out studies in animals to investigate the effect of 1/3 volume toploading infusions on renal function and histology when followed on days 1, 7 and 21 after infusions.
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MATERIALS AND METHODS

Preparation of Hb Solution
SFHb was prepared by the method as previously described [14] . Briefly, SFHb was obtained by hypotonic hemolysis of bovine RBCs and it was made stroma-free by toluene extraction and high-speed centrifugation. The resulting solution contained 10Á15 g Hb/dl.
Preparation of PolyHb
This has been described in detail [14] . Briefly, 0.5 M glutaraldehyde was added and allowed to react for 24 hr at 4 o C under anaerobic conditions with constant stirring. The reaction was stopped with excess 2.0 M lysine HCl at a molar ratio of 100:1 (lysine/Hb). Removal of reactants and free Hb molecules was carried out using dialysis and molecular exclusion chromatography [14] .
Preparation of PEG-PLA NanoHb
This has been described in detail [14] . Briefly, PEG-PLA copolymer was prepared from 1. . Just before use, 150 mg of the PEG-PLA copolymer were dissolved in 8 ml acetone. Fifty mg of hydrogenated soybean phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) were dissolved in 4 ml ethanol. The two solutions were mixed and emulsified with the PolyHb solution to form NanoHb. This could be followed by glutaraldehyde crosslinking to reduce the permeability of the membrane [14] . This was then followed by vacuum solvent extraction to remove the organic solvent and high porosity ultrafiltration to remove unencapsulated Hb or PolyHb [14] .
Toploading
Twenty male Sprague-Dawley rats in the weight range of 300940g were used. They were randomly assigned into 5 groups. Each group received one of the following solutions: (1) NanoHb in Ringer lactates; (2) LactRing as control; (3) SFHb; (4) PolyHb; (5) Autologous rat RBCs.
Rats were anesthetized with sodium pentobarbitum (60 mg/kg), then unilateral femoral vein was cannulated using 3 cm length PE10 tubing (0.28 mm inner, 0.61 mm outer diameter, Clay Adams, Becton Dickinson, Sparks, MD, USA). Each rat received intravenous infusion of 33% of the total blood volume of one of the above 5 solutions. Total blood volume in ml was calculated as 6.5% of body weight in grams.
Blood Chemistry
Blood samples were taken from rats before injections, and on days 1, 7, 21 after injections. Plasma samples were stored in (768C freezer until tested in the analytical laboratory of the McIntyre Animal Centre, McGill University. Blood levels of urea, creatinine, calcium, inorganic phosphorus and electrolytes were determined.
Histology Study
At day 21 after injection of various solutions, rats in all groups were sacrificed and kidneys were excised for histology examination. The kidney was fixed in 10% formalin solution, embedded in paraffin, then cut into serial 5-mm thick sections, mounted on slides, then sections were stained with hematoxylin and eosin (H&E) for histology examination.
Statistics
Blood chemistry assays were presented as mean9S.E. For multiple comparisons of biochemical data in all groups, we performed one-way analysis of variance (ANOVA). A p-value of less than 0.05 was considered significant.
RESULTS
Biochemistry
Toploading of PEG-PLA NanoRBC into rats did not result in any elevation of systemic urea (Figure 1 ). LactRing, PolyHb or autologous RBCs also did not result in any elevations. On the other hand, similar toploading using SFHb resulted in the elevation of urea one day after infusion and the elevated levels were maintained on day 7 and day 21 (Figure 1 ). Figure 2 shows that toploading of PEG-PLA NanoHb into rats did not result in any elevation of systemic creatinine. LactRing, PolyHb or autologous RBCs also did not result in any elevations. Toploading using SFHb resulted in the elevation of creatinine one day after infusion and the elevated levels were maintained on day 7 and day 21 (Figure 2 ). Figure 3 shows that toploading of PEG-PLA NanoRBC into rats did not result in any elevation of uric acid. LactRing, PolyHb or autologous RBCs also did not result in any elevations. But similar toploading using SFHb resulted in the elevation of uric acid one day after infusion and the elevated levels were maintained on day 7 and day 21 (Figure 3) . 
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Figure 4a and Figure 4b show that there were no abnormalities in the plasma calcium and phosphate levels in rats of all infusion groups throughout the 21 days (Figure 4 ).
There were no abnormalities in the plasma sodium and chloride levels in rats of all infusion groups throughout the 21 days ( Figure 5 a and b) .
Renal Histology
The renal glomeruli were not observed remarkably damaged in all infusion groups, with normal number of renal glomerulus, no glomerulus necrosis, distention and degeneration ( Figure 6 ).
When the renal tubular system was examined in rats infused with SFHB, proximal tubular necrosis was observed, and intraluminal cellular debris was found in the proximal tubules, showing that the proximal necrosis occurrence (Figure 7c) . In all the other groups, there were no tubular lesions in the kidneys, no protein or other sediments within the tubular lumens (Figure 7a, b,  d, e) .
DISCUSSION
Strom-free hemoglobins are readily filtered at the glomerulus. In the tubular lumen hemglobin causes hemoglobin-associated nephrotoxicity. In our present study we also observe that SFHb causes renal function damage and proximal This study shows that PEG-PLA Nano artificial bells containing Hb also did not induce renal function disorders, and there were no kidney histology abnormalities. Polymers for forming nanocapsule membranes have to be nontoxic and must be degradable in the body into nontoxic degradation products. Many polymers are not biodegradable and some biodegradable ones like alkyl-cyanoacrylates form toxic degradation products. Other potentially useful 
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biodegradable polymers may release toxic residual monomers or chemicals used in polymerization. Chang's original solvent evaporation method used to prepare PLA microcapsules avoids the need for polymerization [8] . PLA and related polyesters like polyglycolic acids have been approved by the FDA for routine clinical uses in humans as suture materials, bone graft, drug carriers and other areas with no adverse or toxic effects. In the case of PEG, it has 
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adverse effects related to renal function and renal histology. In another study to be reported, we found that PEG-PLA nano artificial red blood cells do not have adverse effects on the reticuloendothelial system.
